- Clinical Trials
- January 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €1431EUR$1,500USD£1,219GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1192EUR$1,250USD£1,016GBP
- Report
- April 2024
- 180 Pages
Global
From €4674EUR$4,900USD£3,981GBP
- Report
- February 2024
- 117 Pages
Global
From €4531EUR$4,750USD£3,859GBP
- Report
- November 2023
- 168 Pages
Global
From €2385EUR$2,500USD£2,031GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4722EUR$4,950USD£4,022GBP
- Report
- April 2024
- 80 Pages
United States
From €2475EUR$2,595USD£2,108GBP
- Report
- April 2024
- 100 Pages
Africa
From €3620EUR$3,795USD£3,083GBP
- Report
- September 2021
- 150 Pages
Global
From €4578EUR$4,799USD£3,899GBP
- Report
- March 2019
- 220 Pages
Global
From €2861EUR$2,999USD£2,437GBP
- Report
- January 2021
- 420 Pages
United States
From €2270EUR$2,380USD£1,934GBP
€2671EUR$2,800USD£2,275GBP
- Report
- May 2023
- 51 Pages
Global
From €3339EUR$3,500USD£2,844GBP
- Report
- November 2020
- 88 Pages
Global
From €1312EUR$1,375USD£1,117GBP
€2623EUR$2,750USD£2,234GBP
- Report
- January 2023
- 125 Pages
Global
From €2375EUR$2,490USD£2,023GBP
- Report
- December 2022
- 196 Pages
Global
From €4800EUR$5,208USD£3,950GBP
- Report
- February 2023
- 244 Pages
Global
From €4007EUR$4,200USD£3,412GBP
- Report
- March 2022
- 75 Pages
Global
From €906EUR$950USD£772GBP
- Report
- February 2023
- 243 Pages
Asia Pacific
From €5294EUR$5,550USD£4,509GBP
- Report
- June 2020
- 163 Pages
Global
From €3959EUR$4,150USD£3,372GBP
The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more